Intrasellar space-occupying lesions are common intracranial disorders whose surgical management requires multidisciplinary collaboration and precise individualized regimens. According to the 2023 Chinese Guidelines for Diagnosis and Treatment of Pituitary Adenomas, the annual incidence of pituitary adenomas ranges from 7.5 to 15 per 100,000 population, accounting for 10%–15% of all intracranial tumors. The widespread adoption of minimally invasive techniques including neuronavigation and endoscopy has significantly elevated gross total resection rates for sellar surgery, yet comprehensive risk assessment remains mandatory preoperatively.

Clinical Manifestations of Intrasellar Masses

Three major categories of symptoms arise from intrasellar lesions:

• Endocrine dysfunction driven by aberrant hormone secretion: Prolactinomas cause amenorrhea-galactorrhea syndrome in approximately 40% of affected patients.

• Mass compressive manifestations: Visual pathway impairment with bitemporal hemianopia occurs in 62% of patients; headache is reported in 78% of cases.

• Hypopituitarism presenting with dysfunction across multiple target gland axes.

Pathological Subtypes of Intrasellar Lesions

Pituitary adenoma pathogenesis involves gene mutations and dysregulated signaling pathways: GNAS mutations correlate with growth hormone-secreting adenomas, while USP8 mutations are characteristic of Cushing’s disease. The 2024 WHO classification of pituitary neuroendocrine tumors establishes novel subtypes such as oncocytomas and sparsely granulated adenomas, which directly guide therapeutic decision-making.

Surgical Indications for Intrasellar Space-Occupying Lesions

Surgical resection is indicated for the following scenarios:

• Progressive visual loss secondary to optic nerve compression;

•Severe hormonal hypersecretion refractory to medical therapy;

• Pituitary apoplexy accompanied by acute neurological deficits;

Clinically overt masses with diameter >1 cm.

Data from the Chinese Pituitary Disease Registry Center shows 68% of surgical cases in 2023 underwent resection due to visual pathway compression.

Key Preoperative Evaluation Procedures

Complete preoperative workup includes:

• Full endocrine panel assessing all six pituitary-target gland axes;

• High-resolution thin-slice pituitary MRI (1 mm slice thickness);

Visual evoked potentials and automated perimetry.

Special cardiac function screening is required, as acromegalic patients frequently develop cardiomyopathy.

Surgical Approach Selection Strategy

The transnasal transsphenoidal corridor represents the dominant modern approach, offering minimal tissue trauma and rapid postoperative recovery. Giant lesions with extensive suprasellar extension may require extended transsphenoidal approaches or craniotomy. Combined neuronavigation and endoscopy lifts gross total resection rates up to 85%.

Intraoperative Risks and Countermeasures

Major operative risks include internal carotid artery injury (0.4%–1.2%), cerebrospinal fluid rhinorrhea (3.1%–8%), diabetes insipidus (18% transient, 2% permanent). Intraoperative Doppler ultrasound and neuronavigation effectively reduce vascular injury risk.

Prevention and Management of Postoperative Complications

Close monitoring of fluid-electrolyte balance, particularly serum sodium fluctuations, is mandatory postoperatively. Diabetes insipidus typically develops within 24–48 hours after surgery, with desmopressin as first-line therapy. Cerebrospinal fluid leaks are managed via lumbar drainage or secondary dural repair surgery.

Perioperative Endocrine Management

Glucocorticoid replacement is the cornerstone of postoperative care. Prophylaxis for adrenal insufficiency is critical for patients with Cushing’s disease. Serial hormonal surveillance continues for 3–6 months after hospital discharge.

Long-Term Follow-Up Protocol for Intrasellar Lesions

Postoperative surveillance consists of serial pituitary MRI (3, 6, 12 months postoperatively, then annual scans), comprehensive endocrine profiling and regular visual field testing. Recurrence risk varies by histology; non-functioning adenomas carry a 10-year recurrence rate of approximately 16%.

Analysis of Prognostic Determinants

Favorable prognostic factors include complete gross total resection, mild preoperative visual impairment, and Ki-67 proliferation index <3%. Data from the Chinese Pituitary Adenoma Alliance demonstrates transsphenoidal surgical mortality has fallen below 0.5%, with vascular injury as the leading cause of perioperative death.

Outlook for Emerging Therapeutic Technologies

Novel modalities including high-definition endoscopy, intraoperative MRI and robot-assisted surgery continuously improve surgical outcomes. Molecular targeted agents such as temozolomide achieve a 60% response rate for invasive refractory pituitary adenomas.

Rehabilitation Lifestyle Guidance

Patients requiring lifelong endocrine replacement therapy need regular bone mineral density screening for osteoporosis prevention. A high-protein, high-calcium diet is recommended, with avoidance of rapid excessive weight gain.

Frequently Asked Clinical Questions

Q1: How are residual tumor cells managed after intrasellar mass surgery?

For postoperative residual lesions, individualized strategies are selected based on histopathological subtype: serial observation, radiotherapy or long-term medical suppression. Dopamine agonists are first-line for residual prolactinomas; Gamma Knife stereotactic radiosurgery is offered for other subtypes.

Q2: What are the primary risks of intrasellar lesion surgery?

Core operative hazards include internal carotid artery injury, cerebrospinal fluid leak, diabetes insipidus and worsening visual dysfunction. High-volume specialized pituitary teams restrict severe major complication rates below 3%.

Q3: What clinical manifestations arise from intrasellar space-occupying lesions?

Typical presentations include persistent headache, progressive visual loss, menstrual irregularities and hypogonadism. A subset of patients develop pathognomonic acromegalic or Cushingoid phenotypic changes.

Q4: What renders intrasellar mass surgery technically challenging?

Surgical corridors are extremely narrow, surrounded by vital structures including the optic nerve and internal carotid artery. Additional technical barriers include variable tumor consistency and hypervascularity.